Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus

Published:2021-10-14 Issue: Volume: Page:
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Lin Zuan,Zhang Xuanye,Zhou Yixin,Chen Chen,He Li-na,Li Haifeng,Wang Yuhong,Chen Tao,Hong Shaodong^ORCID,Zhang Li

Funder

the National Natural Science Funds of China

the Outstanding Young Talents Program of Sun Yat-sen University Cancer Center

the Natural Science Foundation of Guangdong Province

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-021-03082-4.pdf

Reference28 articles.

1. Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135. https://doi.org/10.1056/NEJMoa1504627

2. Ready N, Farago AF, de Braud F et al (2019) Third-line nivolumab monotherapy in recurrent SCLC: checkmate 032. J Thorac Oncol 14:237–244. https://doi.org/10.1016/j.jtho.2018.10.003

3. Ribrag V, Avigan DE, Green DJ et al (2019) Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013. Br J Haematol 186:e41–e44. https://doi.org/10.1111/bjh.15888

4. Chen R, Zinzani PL, Lee HJ et al (2019) Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood 134:1144–1153. https://doi.org/10.1182/blood.2019000324

5. Mehra R, Seiwert TY, Gupta S et al (2018) Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer 119:153–159. https://doi.org/10.1038/s41416-018-0131-9

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of nivolumab monotherapy in five cancer types: pooled analysis of post-marketing surveillance in Japan;International Journal of Clinical Oncology;2024-06-06

2. Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors;Journal of Immunotherapy and Precision Oncology;2024-05-01

3. The ABC of Immune-Mediated Hepatitis during Immunotherapy in Patients with Cancer: From Pathogenesis to Multidisciplinary Management;Cancers;2024-02-15

4. Liver Injury and Its Impact on Prognosis in Patients with HBV-Related Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors;Journal of Hepatocellular Carcinoma;2024-01

5. Serum vitamin D deficiency is associated with increased risk of γδ T cell exhaustion in HBV‐infected patients;Immunology;2023-09-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3